Photocure (LSE:0IMT) - Aandelenkoers, Nieuws & Analyse

0IMT Overzicht aandelen

0IMT fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	4/6
Prestaties in het verleden	3/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 86.7% onder onze schatting van de reële waarde

De winst zal naar verwachting met 94.94% per jaar groeien

Dit jaar winstgevend geworden

Risicoanalyse

Geen risico's gedetecteerd voor 0IMT uit onze risicocontroles.

Photocure ASA Concurrenten

Animalcare Group

AIM:ANCR

UK£147.9m

ECO Animal Health Group

AIM:EAH

UK£48.8m

Hikma Pharmaceuticals

LSE:HIK

UK£4.3b

hVIVO

AIM:HVO

UK£148.0m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Photocure
Historische aandelenkoersen
Huidige aandelenkoers	NOK 48.95
52 Week Hoogtepunt	NOK 71.90
52 Week Laag	NOK 48.05
Bèta	0.99
11 maand verandering	-4.21%
3 maanden verandering	-8.33%
1 Jaar Verandering	-1.61%
33 jaar verandering	-48.82%
5 jaar verandering	-47.90%
Verandering sinds IPO	7.58%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	0IMT	GB Pharmaceuticals	GB Markt
7D	-5.0%	4.4%	1.7%
1Y	-1.6%	2.0%	9.0%

Rendement versus industrie: 0IMT presteerde slechter dan de UK Pharmaceuticals -sector, die het afgelopen jaar een rendement van 2 % opleverde.

Rendement versus markt: 0IMT presteerde slechter dan UK Market, dat het afgelopen jaar een rendement van 9 % opleverde.

Prijsvolatiliteit

Is 0IMT's price volatile compared to industry and market?
0IMT volatility
0IMT Average Weekly Movement	5.1%
Pharmaceuticals Industry Average Movement	6.7%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.4%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: 0IMT heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van 0IMT is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1993	102	Dan Schneider	www.photocure.com

Photocure ASA houdt zich, samen met haar dochterondernemingen, bezig met onderzoek, ontwikkeling, productie, distributie, marketing en verkoop van farmaceutische producten in Scandinavische landen, Duitsland, Frankrijk, Oostenrijk, het Verenigd Koninkrijk, de Benelux, Italië, andere Europese landen, Canada en de Verenigde Staten. Het bedrijf is actief via de segmenten Commercial Franchise en Development Portfolio. Het bedrijf biedt Hexvix/Cysview aan voor de detectie en behandeling van blaaskanker.

Photocure ASA Samenvatting

Hoe verhouden de winst en inkomsten van Photocure zich tot de beurswaarde?
0IMT fundamentele statistieken
Marktkapitalisatie	NOK 1.34b
Inkomsten(TTM)	NOK 14.16m
Inkomsten(TTM)	NOK 526.25m

94.3x

Koers/Winstverhouding

2.5x

P/S-verhouding

Is 0IMT overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
0IMT resultatenrekening (TTM)
Inkomsten	NOK 526.25m
Kosten van inkomsten	NOK 29.11m
Brutowinst	NOK 497.15m
Overige uitgaven	NOK 482.98m
Inkomsten	NOK 14.16m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.52
Brutomarge	94.47%
Nettowinstmarge	2.69%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde 0IMT op de lange termijn?

Bekijk historische prestaties en vergelijking

0IMT Overzicht aandelen

Beloningen

Risicoanalyse

Photocure ASA Concurrenten

AIM:ANCR

UK£147.9m

AIM:EAH

UK£48.8m

LSE:HIK

UK£4.3b

AIM:HVO

UK£148.0m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Third quarter 2024 earnings released: kr0.13 loss per share (vs kr0.18 loss in 3Q 2023)

Second quarter 2024 earnings released: EPS: kr0.45 (vs kr0.16 in 2Q 2023)

New minor risk - Share price stability

Photocure ASA Announces Board Appointments

First quarter 2024 earnings released: kr0.29 loss per share (vs kr0.43 loss in 1Q 2023)

Photocure ASA Reiterates Financial Guidance for the Year 2024

Recent updates

Third quarter 2024 earnings released: kr0.13 loss per share (vs kr0.18 loss in 3Q 2023)

Second quarter 2024 earnings released: EPS: kr0.45 (vs kr0.16 in 2Q 2023)

New minor risk - Share price stability

Photocure ASA Announces Board Appointments

First quarter 2024 earnings released: kr0.29 loss per share (vs kr0.43 loss in 1Q 2023)

Photocure ASA Reiterates Financial Guidance for the Year 2024

Photocure ASA Announces Pivotal Trial Results and New Real-World Evidence

Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Full year 2023 earnings released: EPS: kr0.01 (vs kr2.66 loss in FY 2022)

Forecast breakeven date pushed back to 2025

Photocure ASA to Report Q4, 2023 Results on Feb 21, 2024

Photocure ASA Partner Asieris Announces New Drug Application Acceptance for Regulatory Review of Hexvix in China

Third quarter 2023 earnings released: kr0.18 loss per share (vs kr0.37 loss in 3Q 2022)

Photocure ASA Announces Change of Board Composition

Director recently bought kr6.5m worth of stock

Photocure Partner Asieris Confirms Hexvix Phase III Clinical Trial in China Meets Endpoint

Second quarter 2023 earnings released: EPS: kr0.16 (vs kr0.68 loss in 2Q 2022)

Photocure Partner Asieris Announces Completion of Enrollment for Hexvix Phase III Clinical Trial in China

Insufficient new directors

Full year 2022 earnings released: kr2.66 loss per share (vs kr1.15 loss in FY 2021)

Forecast breakeven date pushed back to 2024

Full year 2022 earnings released: kr2.66 loss per share (vs kr1.15 loss in FY 2021)

Photocure Asa Announces Clinical Data Presented At ASCO GU Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure ASA to Report First Half, 2023 Results on Aug 09, 2023

Photocure ASA Announces New Evidence Presented At the 22nd Annual Society of Urologic Oncology Meeting Demonstrating That Blue Light Cystoscopy

Third quarter 2022 earnings released: kr0.37 loss per share (vs kr0.27 loss in 3Q 2021)

Photocure Asa Announces Data Presented At the International Bladder Cancer Network (Ibcn) Meeting Demonstrate A Reduction in the Risk of Recurrence with the Use of Blc

PPhotocure ASA Announces the Commercial Availability of Karl Storz's New Blue Light System in the U.S

Photocure ASA Publishes First Results from Laser III Clinical Study in Medical Journal, European Urology

Photocure ASA Announces Continue E Supporting the Global Launch Activities of the New and Improved Blue Light Cystoscopy

Photocure ASA Appoints Anders Neijber as Chief Medical Officer, Global Medical Affairs and Clinical Development

Second quarter 2022 earnings released: kr0.68 loss per share (vs kr0.40 loss in 2Q 2021)

Photocure Asa Provides Update on Anticipated Commercial Availability of Karl Storz's New Blue Light System in the United States

Photocure ASA Presents Positive Data from the Danish National Patient Registry at the 2022 NordUrologisk Forening (NUF) Congongress in Helsinki

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on April 28, 2022.

First quarter 2022 earnings released: kr0.82 loss per share (vs kr0.57 profit in 1Q 2021)

Full year 2021 earnings released: kr1.15 loss per share (vs kr0.91 loss in FY 2020)

Photocure Announces Endotherapeutics Group as New Commercial Partner for Hexvix in Australia & New Zealand

Photocure ASA Announces the Publication of Pre-Clinical Study Results Supporting the Anti-tumor Effect of Hexaminolevulinate with Blue Light in Bladder Cancer model

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Photocure ASA Receives FDA Approval for Use in NMIBC in the U.S

Third quarter 2021 earnings released: kr0.27 loss per share (vs kr0.23 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.37 loss in 2Q 2020)

Photocure ASA Announces the Publication of a Study in the Journal Urologic Oncology

Asieris Announces First Patient Administration in Europe within the Phase III Clinical Trial for APL-1702 (Cevira)

Photocure ASA (OB:PHO) announces an Equity Buyback for 2,682,006 shares, representing 10% of its issued share capital.

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on June 10, 2020.

Photocure ASA Suspends Guidance for 2023

Photocure ASA to Report Q3, 2021 Results on Nov 17, 2021

Asieris Pharmaceuticals and Photocure ASA Expands Strategic Partnership to Bladder Cancer Diagnosis and Surgery in Mainland China and Taiwan

Photocure Partners with Asieris MediTech to Commercialize Hexvix in Mainland China and Taiwan

Photocure Announces New Cevira Patent In Europe

Photocure Launches European Hexvix Operations

Photocure ASA Provides Revenue Guidance for the Year 2020

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf